On July 17, 2019 AUM Biosciences (AUM), an award-winning company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, reported a global license agreement with Inflection Biosciences (Inflection) for exclusive worldwide rights to develop, manufacture and commercialise Inflection’s first-in-class PIM/PI3K/mTOR inhibitors (Press release, Aura Biosciences, JUL 17, 2019, View Source [SID1234537575]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Known as the IBL-300 series of molecules, the agreement will see AUM develop the lead candidate, IBL-302 (hereafter AUM302), which is currently in the pre-clinical stage of development with activity predicted across a range of cancers. It has been evaluated in over 700 cancer cell lines and has shown potential for clinical development in breast cancer, lung cancer, leukaemia and neuroblastoma.

AUM302 is the first ‘oral kinase inhibitor’ to uniquely inhibit three critical cancer targets (pan-PIM kinase, pan-PI3K and mTOR inhibition) via a single molecule1. Kinase inhibitors are drugs that have played an increasingly prominent role in the treatment of cancer2 and inhibiting these three targets has been shown to be more effective than inhibiting them alone.

Mr Vishal Doshi, CEO, AUM Biosciences said: "With 60% of cancers worldwide diagnosed in Asia3, we are committed to accelerating the development of high potential molecules for the benefit of patients in the region. Our unique Asia to global approach to development aims to ensure that crucial drugs are made available for Asian patients in the shortest timeframe, as well as those in need globally."

The license expands AUM’s pipeline following the recently acquired novel and highly selective Mnk inhibitor, AUM001, from Singapore’s Agency for Science, Technology and Research (A*STAR).

"Our dedication to addressing significant unmet need for cancer patients is what drives us to being at the forefront of precision medicine, technology and the delivery of high-quality personalised care. Our collaboration with Inflection Biosciences is now an important part of this dedication," Doshi added.

Mr Darren Cunningham, CEO of Inflection said: "Inflection Biosciences is committed to developing innovative targeted therapeutics for the benefit of cancer patients worldwide. We are pleased to partner with AUM Biosciences who will bring considerable drug development experience and expertise to ensure AUM302 is advanced towards regulatory approval in Asia and globally."

The advancement of AUM302 continues AUM’s focus on developing a robust industry leading pipeline of combinatorial therapies.

Combination therapy, the use of more than one type of therapy in treating a patient, is a hallmark of cancer treatment. The complexity of the disease – including its tendency to spread beyond its original site and become resistant to some drugs – underscores the need for multiple approaches to attack it. As well as being a monotherapy with three different targets, AUM302 has shown excellent combination potential, working to address the major problem of patient resistance to certain drugs.

AUM plans to commence Investigational New Drug (IND) enabling studies for AUM302 by 20201.

On July 17, 2019 Exelixis, Inc. (NASDAQ: EXEL) reported that its second quarter 2019 financial results will be released on Wednesday, July 31, 2019 after the markets close (Press release, Exelixis, JUL 17, 2019, View Source [SID1234537576]). At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6687332 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on August 2, 2019. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6687332. A webcast replay will also be archived on www.exelixis.com for one year.

On July 17, 2019 Penumbra, Inc. (NYSE: PEN) reported that its management team is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA on Wednesday, August 7, 2019 (Press release, Penumbra, JUL 17, 2019, View Source [SID1234537577]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Canaccord Genuity 39th Annual Growth Conference
Date: Wednesday, August 7, 2019
Time: 11:00am ET / 8:00am PT

A webcast of the presentation will be available by visiting the investors’ section of the company’s website at www.penumbrainc.com. The webcast will be available on the company’s website for at least two weeks following the event.

On July 17, 2019, Atreca, Inc. (the "Company") reported that it has entered into a Lease Agreement (the "Temporary Lease") between the Company and ARE-EAST JAMIE COURT, LLC (the "Temporary Landlord") for the lease of approximately 74,788 rentable square feet of office space located at 450 East Jamie Court, South San Francisco, California (the "Jamie Court Property") (Filing, 8-K, Atreca, JUL 17, 2019, View Source [SID1234540076]). The Jamie Court Property is intended to serve as the Company’s temporary headquarters, office and laboratory space, replacing its existing office space at 500 Saginaw Drive, Redwood City, California, while the Company’s permanent headquarters, office and laboratory space is under construction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The term of the Temporary Lease will commence on the date that the Temporary Landlord delivers the premises of the Jamie Court Property to the Company and is targeted for August 1, 2019, and will end on the earliest of (1) 90 days following the substantial completion of certain tenant improvements and construction on the San Carlos Property (as defined below), (2) 90 days following notice from the Temporary Landlord to the Company in the event that certain tenant improvements on the San Carlos Property have not been substantially completed prior to the Rent Commencement Date (as defined below) for any reason other than delays caused by the 835 Industrial Landlord (as defined below), and (3) 90 days following the termination of the 835 Industrial Lease (as defined below) if the 835 Industrial Lease terminates prior to the Rent Commencement Date. The "Rent Commencement Date" is the earlier of (1) 10.5 months following the date that the 835 Industrial Landlord delivers the premises of the San Carlos Property to the Company to begin certain tenant improvements thereto and (2) the date that certain tenant improvements on the San Carlos Property are substantially completed.

The Company’s base rent for the Temporary Lease is $280,455.00 per month, with annual increases of 3% multiplied by the base rent payable of the preceding year. In addition, the Company is responsible for 100% of the operating expenses for the Jamie Court Property (and 45.79% of the project operating expenses) as set forth in the Temporary Lease.

The Temporary Lease also contains customary provisions allowing the Temporary Landlord to terminate the Temporary Lease if the Company fails to remedy a breach of certain of its obligations as set forth in the Temporary Lease within specified time periods, or upon bankruptcy or insolvency of the Company.

Permanent Lease

On July 17, 2019 and concurrently with the execution and delivery of the Temporary Lease, the Company entered into a Lease Agreement (the "835 Industrial Lease") between the Company and ARE-SAN FRANCISCO NO. 63, LLC (the "835 Industrial Landlord") for the lease of approximately 99,557 rentable square feet of office space located at 835 Industrial Road, San Carlos, California (the "San Carlos Property"). The San Carlos Property is intended to serve as the Company’s permanent headquarters, office and laboratory space following the completion of construction on the San Carlos Property.

The term of the 835 Industrial Lease will commence on the date that the 835 Industrial Landlord delivers the premises of the San Carlos Property to the Company for construction of certain tenant improvements and is targeted for August 1, 2020, and will end on the date that is 144 months from the first day of the first full month after the Rent Commencement Date. The Company has the right to extend the term of the 835 Industrial Lease once for five years on substantially the same terms and conditions of the 835 Industrial Lease, subject to market-rate adjustment of the Base Rent pursuant to the terms of the 835 Industrial Lease, by giving the 835 Industrial Landlord written notice at least 9 months but not more than 15 months prior to the expiration of the initial term of the 835 Industrial Lease.

The Company’s base rent for the 835 Industrial Lease is $557,519.20 per month, with annual increases of 3% multiplied by the base rent payable of the preceding year. In addition, the Company is responsible for certain operating expenses as set forth in the 835 Industrial Lease. The Company is also obligated to provide a security deposit of $1,115,038.40.

The first time after the 835 Industrial Landlord leases the leasable space located on the second floor of the building at the San Carlos Property (the "ROFR Space") to another third party that the 835 Industrial Landlord intends to accept another bona fide written proposal to lease the ROFR Space (the "Intended Lease"), the 835 Industrial Landlord shall deliver notice to the Company of the Intended Lease, and the Company shall have a one-time right of first refusal to elect to lease the ROFR Space on the same general terms and conditions of the 835 Industrial Lease, as modified to reflect the terms and conditions of the Intended Lease.

The 835 Industrial Lease also contains customary provisions allowing the 835 Industrial Landlord to terminate the 835 Industrial Lease if the Company fails to remedy a breach of certain of its obligations as set forth in the 835 Industrial Lease within specified time periods, or upon bankruptcy or insolvency of the Company.

The foregoing descriptions of the Temporary Lease and the 835 Industrial Lease are only summaries and are qualified in their entirety by reference to the complete terms and conditions of the Temporary Lease and the 835 Industrial Lease, which are attached as Exhibits 10.18 and 10.19 to this Current Report on Form 8-K and incorporated herein by reference.

On July 17, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that 2019 second quarter financial results will be released on Tuesday, July 30, 2019 after the market closes (Press release, CryoLife, JUL 17, 2019, View Source [SID1234537578]). On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. A replay of the teleconference will be available July 30 through August 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13692463.

The live webcast and replay can be accessed in the Investor Relations section of the CryoLife website at www.cryolife.com and selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investor Relations section of the CryoLife website.